195 related articles for article (PubMed ID: 1372671)
1. [Myeloid growth factors can cure chronic neutropenia and facilitate cytostatic therapy].
Palmblad J; Samuelsson J
Lakartidningen; 1992 Mar; 89(13):1037-8, 1041. PubMed ID: 1372671
[No Abstract] [Full Text] [Related]
2. Cost considerations in therapy with myeloid growth factors.
Glaspy JA; Jakway J
Am J Hosp Pharm; 1993 Jul; 50(7 Suppl 3):S19-26. PubMed ID: 7689789
[TBL] [Abstract][Full Text] [Related]
3. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (2).
Lieschke GJ; Burgess AW
N Engl J Med; 1992 Jul; 327(2):99-106. PubMed ID: 1376442
[No Abstract] [Full Text] [Related]
4. [Clinical use of hematopoietic growth factors].
Krusius T
Duodecim; 1990; 106(7):547-9. PubMed ID: 1727024
[No Abstract] [Full Text] [Related]
5. [Clinical use of granulocyte colony stimulating-factors (GM-CSF and G-CSF].
Borota R; Borota J; Belić A; Gebauer E; Stefanović N
Med Pregl; 1997; 50(3-4):87-93. PubMed ID: 9229690
[TBL] [Abstract][Full Text] [Related]
6. [Hematopoietic growth factors in the treatment of acute myeloblastic leukemia].
de la Rubia Comos J
Sangre (Barc); 1997 Apr; 42 Suppl 1():32-3. PubMed ID: 9381298
[No Abstract] [Full Text] [Related]
7. [Clinical use of hematopoietic growth factors].
Robak T
Pol Tyg Lek; 1992 Apr 20-27; 47(16-17):365-8. PubMed ID: 1279638
[No Abstract] [Full Text] [Related]
8. Haemopoietic growth factors and childhood cancer.
Hann IM
Eur J Cancer; 1995; 31A(9):1476-8. PubMed ID: 7577075
[No Abstract] [Full Text] [Related]
9. [Preventing and treating hematologic complications of anticancer chemotherapy: update on hematopoietic growth factors].
Spaëth D; Geoffrois L; Conroy T
Bull Cancer; 2000 Jan; 87(1):93-6. PubMed ID: 10673637
[No Abstract] [Full Text] [Related]
10. Hematopoietic growth factors in patients receiving intensive chemotherapy for malignant disorders: studies of granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-3 (IL-3) and Flt-3 ligand (Flt3L).
Bruserud O; Foss B; Petersen H
Eur Cytokine Netw; 2001; 12(2):231-8. PubMed ID: 11399510
[TBL] [Abstract][Full Text] [Related]
11. Colony-stimulating factors in cancer therapy.
Morstyn G; Sheridan WP
Cancer Chemother Biol Response Modif; 1992; 13():308-26. PubMed ID: 1382528
[No Abstract] [Full Text] [Related]
12. Treatment of myelodysplastic syndromes with hematopoietic growth factors.
Ganser A; Hoelzer D
Hematol Oncol Clin North Am; 1992 Jun; 6(3):633-53. PubMed ID: 1377194
[TBL] [Abstract][Full Text] [Related]
13. [The dilemma of stimulating factors in the recovery from chemotherapeutic neutropenia].
Borbollo Escoboza JR; González Avante M; Alvarado Ibarra M
Rev Invest Clin; 1996; 48(4):328. PubMed ID: 8966397
[No Abstract] [Full Text] [Related]
14. Hematopoietic growth factors in the reduction of chemotherapeutic toxicity.
Johnston EM; Crawford J
Semin Oncol; 1998 Oct; 25(5):552-61. PubMed ID: 9783594
[TBL] [Abstract][Full Text] [Related]
15. Plasma lactoferrin content in neutropenic patients: effects of treatment with recombinant granulocyte-macrophage colony-stimulating factor.
Bezwoda WR; Dajee D
Mol Biother; 1992 Jun; 4(2):103-6. PubMed ID: 1515094
[TBL] [Abstract][Full Text] [Related]
16. Clinical applications of human granulocyte-macrophage colony-stimulating factor.
Sakamoto KM; Gasson JC
Int J Cell Cloning; 1991 Nov; 9(6):531-41. PubMed ID: 1770227
[TBL] [Abstract][Full Text] [Related]
17. [GM-CSF and G-CSF: cytokines in clinical application].
Ruef C; Coleman DL
Schweiz Med Wochenschr; 1991 Mar; 121(12):397-412. PubMed ID: 1709294
[TBL] [Abstract][Full Text] [Related]
18. [Chronic neutropenia].
Palmblad J; Elinder G
Nord Med; 1996 Nov; 111(9):304-7. PubMed ID: 8966113
[TBL] [Abstract][Full Text] [Related]
19. [Myeloid hemopoietic growth factors. Therapeutic possibilities and clinical experiences].
Hansen B; Johnsen HE
Ugeskr Laeger; 1990 Oct; 152(44):3232-7. PubMed ID: 1700524
[TBL] [Abstract][Full Text] [Related]
20. Fludarabine, cytosine arabinoside, granulocyte-colony stimulating factor with or without idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromes.
Milligan DW; Wheatley K; Burnett AK
Br J Haematol; 2004 Oct; 127(2):238-9. PubMed ID: 15461640
[No Abstract] [Full Text] [Related]
[Next] [New Search]
